{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-102399","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.206805+00:00","generated_at":"2026-05-17T20:58:30.793054+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vera Therapeutics Q2 net loss $76.5M; on track to submit atacicept BLA in Q4 2025","bullets":["Net loss $76.5M ($1.20 per share) vs $33.7M ($0.62) year-over-year; cash $556.8M as of June 30, 2025.","Positive ORIGIN 3 trial: 46% proteinuria reduction with atacicept; 42% vs placebo (p<0.0001).","BLA submission for accelerated approval of atacicept in IgAN expected Q4 2025; commercial launch targeted 2026.","Secured up to $500M credit facility with Oxford Finance, extending cash runway past potential launch.","Initiated PIONEER basket trial for atacicept in expanded IgAN, pMN, FSGS, and MCD populations."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-102399","json":"https://secwatch.observer/filing/0000950170-25-102399.json","markdown":"https://secwatch.observer/filing/0000950170-25-102399.md","text":"https://secwatch.observer/filing/0000950170-25-102399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000095017025102399/0000950170-25-102399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000095017025102399/vera-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:58:30.793054+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}